AbbVie, Pfizer gain FDA OK for novel antibiotic

AbbVie, Pfizer gain FDA OK for novel antibiotic

Dive Brief: The Food and Drug Administration on Friday approved a new combination antibiotic developed by AbbVie and Pfizer for tough-to-treat bacterial infections. The drug, named Emblaveo, is cleared for…
Vertex challenger Sionna prices $191M IPO

Vertex challenger Sionna prices $191M IPO

Sionna Therapeutics on Thursday raised $191 million in an initial public offering that will fund its plan to challenge Vertex Pharmaceuticals’ dominant cystic fibrosis franchise. The company sold nearly 10.6…
23andMe considers a sale as cash runs low

23andMe considers a sale as cash runs low

Dive Brief: 23andMe said Tuesday it is exploring “strategic alternatives,” which could include the sale of the company, a business combination or restructuring. The genetic testing company ended 2024 with…
Sage rebuffs Biogen bid to take it over

Sage rebuffs Biogen bid to take it over

Dive Brief: Sage Therapeutics’ board of directors has turned back partner Biogen’s opportunitistic attempt at a takeover, unanimously rejecting a $469 million offer from Biogen it said “significantly undervalues” the…
J&J oncology sales grow, but shares slide on outlook

J&J oncology sales grow, but shares slide on outlook

Dive Brief: Johnson & Johnson on Wednesday reported modestly higher-than-expected earnings for the fourth quarter, while cautioning that unfavorable currency exchange rates would temper sales growth this year. Adjusted earnings…
What will 2025 hold for biopharma?

What will 2025 hold for biopharma?

Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – inevitably – obesity. Four…
5 questions facing pharma in 2025

5 questions facing pharma in 2025

Typically, the election of a Republican to the White House is welcome news for the biotechnology and pharmaceutical sectors. The incoming administration is a more uncertain prospect, however. President-elect Donald…
Neumora plummets on depression drug data

Neumora plummets on depression drug data

Neumora Therapeutics, a well-funded biotechnology company, lost more than 80% of its value Thursday because its most advanced drug failed a major test. After seeing positive signs in a smaller…
Nuvig pulls in $161M to make better immune drugs

Nuvig pulls in $161M to make better immune drugs

Biotechnology startup Nuvig Therapeutics is the latest emerging immune drug developer to attract investors’ attention, announcing Thursday a $161 million Series B round to bring its lead candidate into mid-stage…
Trump names RFK Jr. as his pick to lead HHS

Trump names RFK Jr. as his pick to lead HHS

President-elect Donald Trump plans to nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services in a controversial choice that would elevate the prominent vaccine skeptic…
7 steps to selecting the right global central lab

7 steps to selecting the right global central lab

For sponsors and CROs, reducing time-to-market and improving patient access to innovative treatments remain pressing challenges and top priorities. From regulatory hurdles and logistical complexities to patient recruitment and retention,…
GPCR drugmaker Septerna amasses $288M in IPO

GPCR drugmaker Septerna amasses $288M in IPO

Septerna, a developer of medicines that target a ubiquitous family of proteins, on Thursday priced a $288 million initial public offering that again showed investors’ support of biotechnology companies that…